Ht144

Lox-IMVI, Malme-3M, M14, Sk-Mel-5, and Sk-Mel-28 were obtained from the Department of Developmental Therapeutics, National Cancer Institute (NCI), HT144 from the American Tissue Culture Centre (ATCC) and WM-115 and WM-266-4 from the European Collection of Cell Cultures (ECACC). Lox-IMVI, Malme-3M, Sk-Mel-5, and Sk-Mel-28 were maintained at 37 °C with 5 % CO₂ in RPMI medium with 10 % FCS (Cambrex). HT144 was maintained in McCoys 5A (Sigma-Aldrich) with 10 % FCS. WM-115 and WM-266- 4 were maintained in MEM media with 10 % FCS, 2 mM L-glutamine, 1 mM NEAA and 1 mM sodium pyruvate (all Gibco). Stock solutions of dasatinib (10 mM) (Sequoia Research Products) were prepared in dimethyl sulfoxide (Sigma-Aldrich).

All starting materials and reagents used in this research were obtained commercially and used without further purification. Element analyses (C, H, and N) were determined with an elemental Vario EL III analyzer (Elementar, Germany). Single-crystal X-ray diffraction data for compounds 1 and 2 were recorded on Mercury CCD diffractometer (Bruker Optics, Germany). The melting points were taken on a XT-4 micro melting apparatus (Ledon, China), and the thermometer was uncorrected. Three human skin cancer cell lines (A-431, HT-144 and SK-MEL-30) were purchased from Sigma-Aldrich (USA).